{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:55:04Z","timestamp":1696463704810},"reference-count":23,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ejps.2013.04.026","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T17:23:25Z","timestamp":1367515405000},"page":"123-129","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Monitoring of imatinib targeted delivery in human leukocytes"],"prefix":"10.1016","volume":"50","author":[{"given":"Eva","family":"Kralj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"\u017dakelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurij","family":"Trontelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadej","family":"Paji\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Prelo\u017enik Zupan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"\u010cernel\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Ostanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janja","family":"Marc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albin","family":"Kristl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2013.04.026_b0005","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2013.04.026_b0010","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronicphase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2013.04.026_b0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpba.2011.10.003","article-title":"HPLC\u2013MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC)","volume":"59","author":"D\u2019Avolioa","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2013.04.026_b0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2013.04.026_b0025","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"JCO"},{"key":"10.1016\/j.ejps.2013.04.026_b0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3324\/haematol.2010.033290","article-title":"OCT-1 function varies with cell lineage but is not influenced by BCR-ABL","volume":"96","author":"Engler","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ejps.2013.04.026_b0040","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/AAC.01407-09","article-title":"Intracellular concentrations of posaconazole in different compartments of peripheral blood","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2013.04.026_b0045","unstructured":"U.S. FDA, Guidance for Industry, Bioanalytical Method Validation, 2001. <http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatory526Information\/Guidances\/UCM07010.pdf> (accessed on 28.01.13)."},{"key":"10.1016\/j.ejps.2013.04.026_b0050","unstructured":"Goldman, J., 2007. Recommendations for the management of BCR-ABL-positive chronic myeloid leukaemia. <http:\/\/www.bcshguidelines.com\/documents\/CML_BCR-ABL_270707.pdf> (accessed 28.01.13)."},{"key":"10.1016\/j.ejps.2013.04.026_b0055","doi-asserted-by":"crossref","first-page":"e40853","DOI":"10.1371\/journal.pone.0040853","article-title":"Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells","volume":"7","author":"Lipka","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2013.04.026_b0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jchromb.2005.11.009","article-title":"Standard line slopes as a measure of a relative matrix effect in quantitative HPLC\u2013MS bioanalysis","volume":"830","author":"Matuszewski","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejps.2013.04.026_b0065","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.talanta.2010.11.028","article-title":"A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells","volume":"83","author":"Mlejnek","year":"2011","journal-title":"Talanta"},{"key":"10.1016\/j.ejps.2013.04.026_b0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2013.04.026_b0075","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2013.04.026_b0080","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ejps.2013.04.026_b0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","article-title":"The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumor","volume":"34","author":"Teng","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2013.04.026_b0090","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2013.04.026_b0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1\u2013mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2013.04.026_b0100","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2013.04.026_b0105","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2013.04.026_b0110","unstructured":"Whole Blood CD15 MicroBeads, 2008. <http:\/\/www.miltenyibiotec.com\/~\/media\/Images\/Products\/Import\/0001100\/IM0001158.ashx> (accessed 28.01.13)."},{"key":"10.1016\/j.ejps.2013.04.026_b0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of \u03b1 1-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.04.026_b0120","unstructured":"Zhong, J.S., Meng, F.Y., Xu, D., Zhou, H.S., Dai, M., 2012. Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia. Zhonghua xue ye xue za zhi. 33, 177\u2013182."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713001693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713001693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T03:50:46Z","timestamp":1539661846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098713001693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0928098713001693"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2013.04.026","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring of imatinib targeted delivery in human leukocytes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2013.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}